



08-09-07

Express Mail No. EB 132 602 322 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaColla, *et al.*

Confirmation No.: 9201

Serial No.: 10/609,298

Art Unit: 1623

Filed: June 27, 2003

Examiner: T. McIntosh III

For: 2' AND 3' NUCLEOSIDE
PRODRUGS FOR TREATING
FLAVIVIRIDAE INFECTIONS

Attorney Docket No.: 11874-016-999
(417451-999016)
IDX 1017

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of References B01 to B10 and C01 to C06 are submitted herewith. References A01 to A13 are U.S. patents and U.S. published applications. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.


Respectfully submitted,

Date: August 7, 2007


Dale L. Rieger

Reg. No. 43,045

JONES DAY
222 East 41st Street
New York, New York 10017
(858) 314-1200



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-016-999	10/609,298
APPLICANT	CONFIRMATION
LaColla, et al.	9201
FILING DATE	ART UNIT
6/27/2003	1623

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	4,880,784	11/14/89	Robins, et al.	
	A02	5,156,797	10/26/93	Chou, et al.	
	A03	5,371,210	12/06/94	Chou, et al.	
	A04	5,401,861	3/28/95	Chou, et al.	
	A05	5,606,048	2/25/97	Chou, et al.	
	A06	5,821,357	10/13/98	Chou, et al.	
	A07	7,157,441	1/02/07	Sommadossi, et al.	
	A08	7,163,929	1/16/07	Sommadossi, et al.	
	A09	2003/0055013	3/20/03	Brass	
	A10	2004/0077587	4/22/04	Sommadossi, et al.	
	A11	2004/0097461	5/20/04	Sommadossi, et al.	
	A12	2004/0101535	5/27/04	Sommadossi, et al.	
	A13	2005/0124532	6/09/05	Sommadossi, et al.	

FOREIGN PATENT DOCUMENTS


*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	GB 1187824	5/02/66	Merck & Co., Inc.		
	B02	WO 99/052514	10/21/99	Eli Lilly and Co.		
	B03	WO 04/065398	8/5/04	Ribapharm, Inc.		
	B04	WO 04/080466	9/23/04	Ribapharm, Inc.		
	B05	WO 05/012327	2/10/05	University College Cardiff Consultants Limited		
	B06	WO 05/021568	3/10/05	Biota, Inc.		
	B07	WO 05/030258	4/07/05	Dihedron Corp.		
	B08	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B09	WO 06/002231	1/05/06	Biocryst Pharmaceuticals, Inc.		
	B10	WO 06/012078	2/02/06	Merck & Co., Inc.		

LAI-2891110v1

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
11874-016-999	10/609,298
APPLICANT	CONFIRMATION
LaColla, et al.	9201
FILING DATE	ART UNIT
6/27/2003	1623

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	Berenguer, M., et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," Proceedings of the Association of American Physicians, 110(2), 98-112 (1998).	
	C02	Kotra, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosides." J. Med. Chem. 1997, 40, 3635-3644.	
	C03	Kuhn, R., et al., "Über eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
	C04	Savochkina, et al., "Substrate Properties of C-MethylNucleoside Triphosphates in RNA Syntheses Catalyzed by E. Coli RNA - Polymerase." Molecular Biology, 1989, v. 23, no. 6.	
	C05	Zinchenko, et al., "2', 3' & .5' - uridine methyl derivatives in microbiological transfection." Doklady Akad Nauk v.297(3), pp. 731-734.	
	C06	Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosphorases in whole cells of e. coli" Biopolymers & a cell, 1988, v. 4, No. 6.	

LA1-2891110v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.